9 research outputs found

    Influência do dreno pleural sobre a dor, capacidade vital e teste de caminhada de seis minutos em pacientes submetidos à ressecção pulmonar Influence of pleural drainage on postoperative pain, vital capacity and six-minute walk test after pulmonary resection

    Get PDF
    OBJETIVO: Avaliar a influência do dreno pleural sobre a distância percorrida no teste de caminhada de seis minutos, da intensidade da dor e da capacidade vital de pacientes submetidos à ressecção pulmonar. MÉTODOS: Foram avaliados treze pacientes consecutivos, internados na Enfermaria da Cirurgia de Tórax do Hospital São Paulo, submetidos à drenagem pleural fechada (dreno tubular multiperfurado de 0,5 polegada), no período pós-operatório de ressecção pulmonar (lobectomia, segmentectomia e nodulectomia). A opção pela retirada do dreno seguiu critérios clínicos definidos por médicos da equipe cirúrgica alheios ao estudo. A determinação da capacidade vital, da intensidade da dor através da escala visual analógica de dor e da distância percorrida no teste de caminhada de seis minutos foram realizadas 30 min antes da retirada do dreno e 30 min após. A análise estatística dos dados foi realizada através do teste t pareado, com nível de significância estabelecido em 0,05. RESULTADOS: Após a retirada do dreno, os valores obtidos na avaliação da escala visual analógica de dor foram significativamente menores (3,46 cm vs. 1,77 cm; p = 0,001), e a distância percorrida no teste de caminhada de seis minutos foi significativamente maior (374,34 m vs. 444,62 m; p = 0,03). A capacidade vital antes e após a retirada do dreno não foi alterada de forma significativa (2,15 L vs. 2,25 L, respectivamente; p = 0,540). CONCLUSÕES: Os resultados deste estudo sugerem que a presença do dreno pleural é um importante fator associado à dor pós-operatória e à limitação funcional em pacientes submetidos à ressecção pulmonar.<br>OBJECTIVE: To evaluate the influence of pleural drainage on the distance covered on the six-minute walk test, pain intensity and vital capacity in patients submitted to pulmonary resection. METHODS: Thirteen consecutive patients from the Thoracic Surgery Infirmary of Hospital São Paulo, Brazil, submitted to closed pleural drainage (0.5-in multiperforated chest tube) in the postoperative period following pulmonary resection (lobectomy, segmentectomy and pulmonary nodule resection) were evaluated. The decision for chest tube removal followed clinical criteria defined by the surgical team, who did not participate in the study. Vital capacity, pain intensity (using a visual analog pain scale) and the distance covered on the six-minute walk test were determined 30 min prior to and 30 min after the removal of the chest tube. The statistical analysis was performed using paired t-tests, and the level of significance was set at 0.05. RESULTS: After the removal of the chest tube, the visual analog scale pain scores were significantly lower (3.46 cm vs. 1.77 cm; p = 0.001) and the distance covered on the six-minute walk test was significantly higher (374.34 m vs. 444.62 m; p = 0.03). Vital capacity prior to and after chest tube removal was not significantly affected (2.15 L and 2.25 L, respectively; p = 0.540). CONCLUSIONS: The results of the present study suggest that the presence of a chest tube is a factor significantly associated with postoperative pain and functional limitation in patients submitted to pulmonary resection

    Effect of lung recruitment and titrated Positive End-Expiratory Pressure (PEEP) vs low PEEP on mortality in patients with acute respiratory distress syndrome - A randomized clinical trial

    No full text
    IMPORTANCE: The effects of recruitment maneuvers and positive end-expiratory pressure (PEEP) titration on clinical outcomes in patients with acute respiratory distress syndrome (ARDS) remain uncertain. OBJECTIVE: To determine if lung recruitment associated with PEEP titration according to the best respiratory-system compliance decreases 28-day mortality of patients with moderate to severe ARDS compared with a conventional low-PEEP strategy. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized trial conducted at 120 intensive care units (ICUs) from 9 countries from November 17, 2011, through April 25, 2017, enrolling adults with moderate to severe ARDS. INTERVENTIONS: An experimental strategy with a lung recruitment maneuver and PEEP titration according to the best respiratory-system compliance (n = 501; experimental group) or a control strategy of low PEEP (n = 509). All patients received volume-assist control mode until weaning. MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality until 28 days. Secondary outcomes were length of ICU and hospital stay; ventilator-free days through day 28; pneumothorax requiring drainage within 7 days; barotrauma within 7 days; and ICU, in-hospital, and 6-month mortality. RESULTS: A total of 1010 patients (37.5% female; mean [SD] age, 50.9 [17.4] years) were enrolled and followed up. At 28 days, 277 of 501 patients (55.3%) in the experimental group and 251 of 509 patients (49.3%) in the control group had died (hazard ratio [HR], 1.20; 95% CI, 1.01 to 1.42; P = .041). Compared with the control group, the experimental group strategy increased 6-month mortality (65.3% vs 59.9%; HR, 1.18; 95% CI, 1.01 to 1.38; P = .04), decreased the number of mean ventilator-free days (5.3 vs 6.4; difference, −1.1; 95% CI, −2.1 to −0.1; P = .03), increased the risk of pneumothorax requiring drainage (3.2% vs 1.2%; difference, 2.0%; 95% CI, 0.0% to 4.0%; P = .03), and the risk of barotrauma (5.6% vs 1.6%; difference, 4.0%; 95% CI, 1.5% to 6.5%; P = .001). There were no significant differences in the length of ICU stay, length of hospital stay, ICU mortality, and in-hospital mortality. CONCLUSIONS AND RELEVANCE: In patients with moderate to severe ARDS, a strategy with lung recruitment and titrated PEEP compared with low PEEP increased 28-day all-cause mortality. These findings do not support the routine use of lung recruitment maneuver and PEEP titration in these patients. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01374022
    corecore